Digoxin Kinetics calculator. (Pharmacokinetics). Program by D.McAuley

All calculations must be confirmed before use. The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgement. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material.

PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Disclaimer

Digoxin Dosing Calculator
Determination of initial loading and maintanance dose.
This document Copyright © 2006 GlobalRPh. All Rights Reserved
Patient name: Floor:

Age: | | Scr(mg/dl):

Height: | Weight:

Select disease state:

Enter desired Cpeak: Dosage form: Acute CHF?
Interacting drugs:
Dosing schedule

If steady state levels are available, use this table instead.
Click here or program information.

References:

Aronson JK: Clinical pharmacokinetics of cardiac glycosides in patients with renal dysfunction. Clin Pharmacokinet 1983; 8:155-178.

Behr ER, Veysey MJ, Berry D, Volans GN. Optimum dose of digoxin. Lancet. 1997 Jun 21;349(9068):1845

Bennett WM, Aronoff GR, Golper TA et al: Drug Prescribing in Renal Failure. American College of Physicians, Philadelphia, PA, 1987.

Cauffield JS, Gums JG, Grauer K. The serum digoxin concentration: ten questions to ask. Am Fam Physician. 1997 Aug;56(2):495-503, 509-10

Cheng JW, Charland SL, Shaw LM, Kobrin S, Goldfarb S, Stanek EJ, Spinler SA. Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay. Pharmacotherapy. 1997 May-Jun;17(3):584-90.

Fenster PE, Hager WD & Goodman MM: Digoxin-quinidine-spironolactone interaction. Clin Pharmacol Ther 1984; 36:70-73.

Gilman AG, Rall TW, Nies AS et al (Eds): Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed. Macmillan Publishing Co, New York, NY, 1990.

Hammerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications.
Clin Pharmacokinet. 1998 Jul;35(1):49-64.

Hui J, Wang YM, Chandrasekaran A, Geraets DR, Caldwell JH, Robertson LW, Reuning RH. Disposition of tablet and capsule formulations of digoxin in the elderly. Pharmacotherapy. 1994 Sep-Oct;14(5):607-12.

Jelliffe, 1968; Product information Lanoxin (R), Glaxo Wellcome Inc. (Jelliffe RW: An improved method digoxin therapy. Ann Intern Med 1968; 69:703.)

Jusko WJ, Szefler SJ & Goldfarb AL: Pharmacokinetic design of digoxin dosage regimens in relation to renal function. J Clin Pharmacol, 1974; 14:525-535.

Koda-Kimble MA: Congestive heart failure, in Applied Therapeutics for Clinical Pharmacists, 2nd ed, edited by Koda-Kimble et al, Applied Therapeutics, Inc., San Francisco 1978; pp 161-86.

Kramer WG, Lewis RP, Cobb TC et al: Pharmacokinetics of digoxin: comparison of a two and a three compartment model in man. J Pharmacokinet Biopharm 1974; 2:299.

Lee CH, Park YJ, Sands CD, Jones DW, Trang JM. Bioavailability of digoxin tablets in healthy volunteers. Arch Pharm Res. 1994 Apr;17(2):80-6.

Mooradian AD: Digitalis: An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. Clin Pharmacokinet 1988; 15:165-179.